CL2021002883A1 - Moduladores de thr-ß y métodos de uso de estos - Google Patents

Moduladores de thr-ß y métodos de uso de estos

Info

Publication number
CL2021002883A1
CL2021002883A1 CL2021002883A CL2021002883A CL2021002883A1 CL 2021002883 A1 CL2021002883 A1 CL 2021002883A1 CL 2021002883 A CL2021002883 A CL 2021002883A CL 2021002883 A CL2021002883 A CL 2021002883A CL 2021002883 A1 CL2021002883 A1 CL 2021002883A1
Authority
CL
Chile
Prior art keywords
formula
methods
thr
modulators
disclosed
Prior art date
Application number
CL2021002883A
Other languages
English (en)
Inventor
Koen Vandyck
Pierre Jean-Marie Bernard Raboisson
David Mcgowan
Jerome Deval
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of CL2021002883A1 publication Critical patent/CL2021002883A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se divulgan compuestos de la Fórmula I: (I) TL-La-CE-HD o una sal, profármaco, amida o éster aceptable desde el punto de vista farmacéutico de estos, donde i) TL es una porción de la Fórmula IIa, IIb, IIIa, IIIb, IIIc o IIId; ii) CE es una porción de la Fórmula IV; iii) HD es una porción de la Fórmula V o VI; donde los sustituyentes son como se definen en la presente. También se divulgan composiciones farmacéuticas que comprenden los compuestos anteriores y métodos para tratar enfermedades mediante la administración o el contacto de un paciente con uno o más de los compuestos anteriores.
CL2021002883A 2019-05-08 2021-11-03 Moduladores de thr-ß y métodos de uso de estos CL2021002883A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845252P 2019-05-08 2019-05-08
US201962944052P 2019-12-05 2019-12-05
US202063005661P 2020-04-06 2020-04-06

Publications (1)

Publication Number Publication Date
CL2021002883A1 true CL2021002883A1 (es) 2022-10-28

Family

ID=70919081

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002883A CL2021002883A1 (es) 2019-05-08 2021-11-03 Moduladores de thr-ß y métodos de uso de estos

Country Status (17)

Country Link
US (2) US11091467B2 (es)
EP (1) EP3965884A1 (es)
JP (1) JP2022532706A (es)
KR (1) KR20220017917A (es)
CN (1) CN114096531A (es)
AU (1) AU2020267576A1 (es)
BR (1) BR112021021718A2 (es)
CA (1) CA3139101A1 (es)
CL (1) CL2021002883A1 (es)
CO (1) CO2021015698A2 (es)
IL (1) IL287720A (es)
MA (1) MA55890A (es)
MX (1) MX2021013472A (es)
PE (1) PE20220255A1 (es)
SG (1) SG11202111552YA (es)
TW (1) TW202108569A (es)
WO (1) WO2020227549A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55890A (fr) * 2019-05-08 2022-03-16 Aligos Therapeutics Inc Modulateurs de thr-beta et leurs procédés d'utilisation
CN113454069A (zh) * 2019-11-26 2021-09-28 昆药集团股份有限公司 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用
CN114787153A (zh) * 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
AU2021341182A1 (en) * 2020-09-10 2023-04-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of resmetirom, preparation method therefor, and use thereof
CA3197234A1 (en) * 2020-11-06 2022-05-12 David Craig Mcgowan Pyridazinone derivatives as thyroid receptor agonists and uses thereof
EP4240722A1 (en) 2020-11-06 2023-09-13 Aligos Therapeutics, Inc. Oxindoles and methods of use thereof
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
IL305495A (en) * 2021-03-03 2023-10-01 Terns Pharmaceuticals Inc Thyroid hormone receptor beta agonist compounds
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
TW202313615A (zh) * 2021-05-21 2023-04-01 大陸商深圳微芯生物科技股份有限公司 一種雜環化合物及其應用
WO2023023474A1 (en) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
WO2023034937A1 (en) 2021-09-01 2023-03-09 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
KR20240053635A (ko) 2021-09-08 2024-04-24 알리고스 테라퓨틱스 인코포레이티드 변형된 짧은 간섭 핵산 (sina) 분자 및 그의 용도
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
PT1088819E (pt) 1999-09-30 2005-09-30 Pfizer Prod Inc Derivados de 6-azauracilo como lignados de receptores da tiroide
EP1262177B1 (en) 2001-05-31 2006-08-23 Pfizer Products Inc. Medical use of thyromimetic compounds to treat hair loss and compositions
EP1471049A4 (en) 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
AU2003265336B8 (en) 2002-07-29 2009-04-23 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2003278544A1 (en) 2002-11-25 2004-06-18 Pfizer Products Inc. Method for promoting nail growth using thyromimetic compounds
MX2008000818A (es) * 2005-07-21 2008-03-18 Hoffmann La Roche Derivados de piridazinona como agonistas del receptor de la hormona tiroidea.
KR20080087833A (ko) * 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
CA2655913A1 (en) * 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 6-5 system bicyclic heterocyclic derivative and its pharmaceutical utility
WO2008104752A1 (en) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
EP2423194B1 (en) 2009-04-20 2014-04-16 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone beta receptor agonist
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
ES2528392T3 (es) 2012-08-06 2015-02-09 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Eprotiroma para su uso en la prevención y/o tratamiento de trastornos capilares y composiciones de la misma
TWI804870B (zh) 2012-09-17 2023-06-11 美商瑪德瑞高製藥公司 用以合成甲狀腺激素類似物及其多形體之方法
WO2015005901A1 (en) 2013-07-09 2015-01-15 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
US10303567B2 (en) 2013-08-15 2019-05-28 Entit Software Llc Managing database nodes
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
SG11201705361PA (en) 2015-01-09 2017-08-30 Gilead Apollo Llc Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
EP3463350B1 (en) 2016-06-03 2023-09-13 ChemoCentryx, Inc. Pyrrolo-pyridines and pyrrolo-pyrimidines for use in treating liver fibrosis
KR20230156159A (ko) 2016-10-18 2023-11-13 마드리갈 파마슈티칼스, 인크. Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법
CN110430876A (zh) 2017-03-13 2019-11-08 基恩菲特公司 用于组合疗法的药物组合物
MX2019012535A (es) 2017-04-18 2020-08-17 Genfit Combinacion que comprende un agonista de ppar tal como elafibranor y un inhibidor de la acetil-coa carboxilasa (acc).
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
JP7273022B2 (ja) 2017-07-19 2023-05-12 バイオ―ラッド ヨーロッパ ゲーエムベーハー 非アルコール性脂肪性肝炎及び肝線維症ステータスを同時に評価するバイオマーカの組み合わせ
WO2019099457A1 (en) 2017-11-14 2019-05-23 Quixgen, Inc. Benzodioxinone compounds
SG11202005007VA (en) 2017-12-06 2020-06-29 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
EP3765059A4 (en) 2018-03-12 2022-01-12 Yale University METHODS OF TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME
EP3787618A4 (en) 2018-05-04 2022-05-04 Cirius Therapeutics, Inc. THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES
CN108727344A (zh) 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
AU2019287679B2 (en) * 2018-06-12 2022-04-21 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
EP3806832A1 (en) 2018-06-14 2021-04-21 Alma Mater Studiorum - Università di Bologna Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug
WO2019242766A1 (zh) 2018-06-22 2019-12-26 成都海创药业有限公司 氘代mgl-3196化合物及其用途
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
EP3840755A4 (en) 2018-08-24 2022-04-20 Terns, Inc. THYROID HORMONE BETA RECEPTOR AGONIST COMPOUNDS
CA3114015A1 (en) 2018-10-12 2020-04-16 Terns, Inc. Thyroid hormone receptor beta agonist compounds
KR20210076932A (ko) * 2018-10-12 2021-06-24 인벤티스바이오 컴퍼니 리미티드 갑상선 호르몬 수용체 작용제
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020169069A1 (en) 2019-02-21 2020-08-27 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
MA55890A (fr) * 2019-05-08 2022-03-16 Aligos Therapeutics Inc Modulateurs de thr-beta et leurs procédés d'utilisation
TW202108556A (zh) 2019-05-10 2021-03-01 大陸商深圳微芯生物科技股份有限公司 一種噠嗪酮衍生物及其應用
IT201900006923A1 (it) 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
TW202115029A (zh) 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
AU2020334943A1 (en) 2019-08-19 2022-03-10 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
US20220281849A1 (en) 2019-08-23 2022-09-08 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN112442013B (zh) 2019-09-04 2022-07-26 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
JP2022549009A (ja) 2019-09-24 2022-11-22 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 甲状腺ホルモンベータ受容体アゴニストとしての化合物及びその使用

Also Published As

Publication number Publication date
BR112021021718A2 (pt) 2022-01-18
US20200354345A1 (en) 2020-11-12
CA3139101A1 (en) 2020-11-12
CN114096531A (zh) 2022-02-25
JP2022532706A (ja) 2022-07-19
IL287720A (en) 2021-12-01
TW202108569A (zh) 2021-03-01
CO2021015698A2 (es) 2022-01-17
PE20220255A1 (es) 2022-02-16
WO2020227549A1 (en) 2020-11-12
AU2020267576A1 (en) 2021-12-09
US20210355112A1 (en) 2021-11-18
EP3965884A1 (en) 2022-03-16
SG11202111552YA (en) 2021-11-29
WO2020227549A8 (en) 2021-05-27
KR20220017917A (ko) 2022-02-14
MX2021013472A (es) 2022-01-06
US11091467B2 (en) 2021-08-17
MA55890A (fr) 2022-03-16

Similar Documents

Publication Publication Date Title
CL2021002883A1 (es) Moduladores de thr-ß y métodos de uso de estos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
PE20221910A1 (es) Derivados de pirazolilo utiles como agentes anticancerigenos
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
PE20210176A1 (es) Inhibidores de arginasa y sus metodos de uso
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2021014210A2 (es) Compuestos de pirrol
PE20210478A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CL2022000892A1 (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
ECSP23089582A (es) Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
CO2021011039A2 (es) Inhibidores de arginasa y métodos de uso de estos
CO2021017202A2 (es) Compuestos tricíclicos
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
UY38072A (es) Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello